Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 21 2021 - 08:00AM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a
biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat progressive
non-viral liver diseases, today announced that Jerry Durso,
President and Chief Executive Officer of Intercept, M. Michelle
Berrey, M.D., M.P.H., President of Research & Development and
Chief Medical Officer of Intercept, Linda Richardson, Chief
Commercial Officer of Intercept, and Andrew Saik, Chief Financial
Officer of Intercept, will present at the 2021 Cantor Virtual
Global Healthcare Conference on Tuesday, September 28,
2021 at 8:40 a.m. ET.
A live webcast of the event will be available on the investor
page of Intercept’s website at http://ir.interceptpharma.com.
An audio archive of the webcast will also be available on
Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat
progressive non-viral liver diseases, including primary biliary
cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded
in 2002 in New York, Intercept has operations in the
United States, Europe and Canada. For more
information, please visit www.interceptpharma.com or
connect with the company
on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:Investor
inquiries: investors@interceptpharma.comMedia
inquiries: media@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Mar 2023 to Mar 2024